- Ab00525-1.1 Anti-CA125 [196-14]
- Mouse IgG1
- Ships in 4-5 weeks
- Ab00525-10.0 Anti-CA125 [196-14]
- Human IgG1
- In Stock
Recombinant monoclonal antibody to CA125. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma 196-14.
UniProt Accession Number of Target Protein: Q8WXI7
Alternative Name(s) of Target: MUC16; Cancer antigen 125; carcinoma antigen 125; carbohydrate antigen 125; mucin 16
Immunogen: HOUA-1 cells from endometrial cancer.
Specificity: The antibody binds to CA125 with a Kd of 0.83 nM reported for the original antibody.
Application Notes: The antibody binds specifically to CA125, membrane associated glycoprotein which acts as a biomarker for ovarian cancer detection, and is also associated with endometrial, fallopian tube, lung, breast and gastrointestinal tract cancers. CA125 plays an important role in tumorigenesis by enhancing the metastasis of tumour cells, increasing immune system evasion, inducing motility and resistance to chemotherapy. The monoclonal antibody 196-14 can be used for both in vivo and in vitro applications, and potentially in the diagnosis and treatment of endometrial or ovarian cancers expressing high levels of CA125.
Antibody first published in:
Saga T, Ishiwata I, Endo K, Sakahara H, Koizumi M, Watanabe Y, Nakai T, Hosono M, Ishikawa H, Sawada M. An antibody-tumor model for the targeting of CA125-producing gynecologic malignancies. Jpn J Cancer Res. 1990 Nov;81(11):1141-8. PMID:2125039
Note on publication: Describes the generation of two monoclonal antibodies reactive against the ovarian cancer-associated antigen CA125.